A study-by-study look at creatine in postmenopausal women, keeping lean mass, strength, bone density, bone geometry, and fracture risk separate.
Quick answer: In postmenopausal women, the most consistent creatine findings are modest gains in lean mass and strength, especially when creatine is combined with resistance training. Bone mineral density has not improved overall. Some studies found better preservation of bone geometry, which is a different outcome. Fracture risk has not been directly established.
The 2026 systematic review and meta-analysis included seven randomized controlled trials and 608 postmenopausal women. The mean age was about 62 years, and trial durations ranged from 12 to 104 weeks. Doses varied. Some trials used 5 g/day, one used 3 g/day for two years, one used 1 g/day for one year, and one used a loading phase followed by 5 g/day. Several trials paired creatine with resistance training.
This is important for perimenopausal readers: the evidence base is mainly postmenopausal. It should not be presented as if it directly studied the full menopause transition.
In the 2026 meta-analysis, pooled lean mass favored creatine by 0.37 kg, with a 95% confidence interval from 0.05 to 0.69 kg. Leg-press one-repetition maximum favored creatine by 7.5 kg, with a 95% confidence interval from 2.2 to 12.8 kg.
The review found that benefits were evident in trials using at least 5 g/day with resistance training. Trials using 3 g/day or less without resistance training did not show measurable benefit. This is a subgroup observation from the included studies, not a personal dosing prescription.
Bone mineral density, or BMD, is the amount of mineral measured in a defined bone area. The 2026 meta-analysis found no overall improvement in BMD with creatine.
A 2015 randomized trial followed 47 postmenopausal women who were assigned to creatine or placebo during a supervised resistance-training program. Thirty-three completed the 12-month analysis. Femoral-neck BMD declined in both groups, but the decline was smaller with creatine: 1.2% versus 3.9% with placebo. That is slowed loss, not a density gain.
A larger 2023 two-year randomized trial enrolled 237 postmenopausal women in an exercise program. Creatine had no effect on BMD at the femoral neck, total hip, or lumbar spine compared with placebo.
Bone geometry describes structural features such as width and resistance to bending. It is not the same as BMD.
In the 2015 trial, creatine increased femoral shaft subperiosteal width compared with placebo. In the 2023 trial, creatine maintained section modulus and buckling ratio better than placebo at the narrow part of the femoral neck. Those are geometric outcomes. They do not mean the bone became denser, and they do not prove fewer fractures.
The trials above were not fracture-prevention trials. A favorable change in a geometric measure can be biologically interesting, but it cannot be translated into “creatine prevents fractures” without direct fracture-outcome evidence.
In the 2023 trial, the creatine group improved 80-meter walking time relative to placebo. The trial did not find a creatine advantage for one-repetition maximum bench press or hack squat strength in the full analysis. A valid-completer subanalysis found a lean-tissue advantage, but subanalyses should be interpreted more cautiously than primary outcomes.
The best-supported practical interpretation is narrow: in postmenopausal women, creatine appears most useful as an adjunct to resistance training for lean mass and strength. The evidence does not establish creatine as a treatment for low bone density or osteoporosis.
If you want to compare a steady dose with loading, use the creatine dose calculator and read the loading comparison. For the broader audience guide, see Creatine for Women. For habit-building, see the first-month guide and timing guide.
Many menopause studies combine creatine with exercise, which makes the combination more relevant than creatine alone. Some outcomes are secondary rather than primary endpoints. Trial adherence also matters, particularly in long studies.
Next: Get your personal dose number from the calculator, then pair it with the first-month routine.
Editorial note: This page is informational and does not provide personalized medical advice. Study findings describe groups, not guarantees for individuals. If you have a medical condition, take prescription medication, are pregnant, or have symptoms that concern you, discuss supplement use with a qualified clinician.